Literature DB >> 18497055

Involvement of a JAK/STAT pathway inhibitor: cytokine inducible SH2 containing protein in breast cancer.

Sahra Borgés1, Elara Moudilou, Cécile Vouyovitch, Jean Chiesa, Peter Lobie, Hichem Mertani, Mireille Raccurt.   

Abstract

Cytokines and growth factors are responsible for inducing the expression of suppressor of cytokine signaling (SOCS) and cytokine-inducible SH2 containing (CIS) proteins. SOCS and CIS proteins are negative regulators of the JAK/STAT pathway, and exert their physiological effects by suppressing the tyrosine kinase activity of cytokine receptors and inhibiting STAT activation. Growth hormone (GH) is considered as a true cytokine and its local production directly contributes to tumor progression. In an initial study, we have found that CIS expression is increased in human breast cancer in proliferative areas corresponding to high level of GH synthesis. The results of the study presented here confirm the presence of a negative feed back loop in MCF7 cells stably transfected with the hGH gene (MCF-hGH). Real-time PCR analysis showed that gene expression levels of CIS were increased by 80% in MCF-hGH cells as compared to control cell line. Similarly, we have found that the level of CIS gene expression is increased by 50% in primary cultures of human breast cancer, reinforcing the pathophysiological impact of CIS. We previously demonstrated that increasing levels of transfected CIS resulted in strong activation of the mitogen-activated protein (MAP) kinase pathway. Thus, CIS protein has been hypothesized as acting like an activator of the MAPK pathway and an inhibitor of the differentiated cells functions mediated through the JAK/STAT pathway. In the present study, we demonstrate the role of CIS protein in tumor progression in particular its positive effects on cell proliferation and colony formation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18497055     DOI: 10.1007/978-0-387-69080-3_30

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  8 in total

1.  HDAC6 Deacetylates HMGN2 to Regulate Stat5a Activity and Breast Cancer Growth.

Authors:  Terry R Medler; Justin M Craig; Alyson A Fiorillo; Yvonne B Feeney; J Chuck Harrell; Charles V Clevenger
Journal:  Mol Cancer Res       Date:  2016-06-29       Impact factor: 5.852

2.  B7-H3 promotes multiple myeloma cell survival and proliferation by ROS-dependent activation of Src/STAT3 and c-Cbl-mediated degradation of SOCS3.

Authors:  Liang Lin; Li Cao; Yang Liu; Ke Wang; Xinwei Zhang; Xiaodan Qin; Dandan Zhao; Jie Hao; Yingjun Chang; Xiaojun Huang; Bei Liu; Jun Zhang; Jin Lu; Qing Ge
Journal:  Leukemia       Date:  2018-12-20       Impact factor: 11.528

3.  Role of c-Myb during prolactin-induced signal transducer and activator of transcription 5a signaling in breast cancer cells.

Authors:  Feng Fang; Michael A Rycyzyn; Charles V Clevenger
Journal:  Endocrinology       Date:  2008-11-26       Impact factor: 4.736

Review 4.  Targeted therapies in gynecological cancers: a comprehensive review of clinical evidence.

Authors:  Qiao Wang; Hongling Peng; Xiaorong Qi; Min Wu; Xia Zhao
Journal:  Signal Transduct Target Ther       Date:  2020-07-29

5.  Esculetin Inhibits Proliferation, Invasion, and Migration of Laryngeal Cancer In Vitro and In Vivo by Inhibiting Janus Kinas (JAK)-Signal Transducer and Activator of Transcription-3 (STAT3) Activation.

Authors:  Geng Zhang; Yi Xu; Hui-Fang Zhou
Journal:  Med Sci Monit       Date:  2019-10-20

6.  Polymorphisms in CISH gene are associated with persistent hepatitis B virus infection in Han Chinese population.

Authors:  Zhangyong Hu; Jinliang Yang; Yangping Wu; Guolian Xiong; Yali Wang; Jun Yang; Lan Deng
Journal:  PLoS One       Date:  2014-06-25       Impact factor: 3.240

7.  Caffeic Acid Versus Caffeic Acid Phenethyl Ester in the Treatment of Breast Cancer MCF-7 Cells: Migration Rate Inhibition.

Authors:  Agata Kabała-Dzik; Anna Rzepecka-Stojko; Robert Kubina; Robert Dariusz Wojtyczka; Ewa Buszman; Jerzy Stojko
Journal:  Integr Cancer Ther       Date:  2018-09-24       Impact factor: 3.279

Review 8.  Quercetin as a Novel Therapeutic Approach for Lymphoma.

Authors:  Saiedeh Razi Soofiyani; Kamran Hosseini; Haleh Forouhandeh; Tohid Ghasemnejad; Vahideh Tarhriz; Parina Asgharian; Željko Reiner; Javad Sharifi-Rad; William C Cho
Journal:  Oxid Med Cell Longev       Date:  2021-08-02       Impact factor: 6.543

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.